| Assessment Status |
NCPE Assessment Process Complete |
| HTA ID |
- |
| Drug |
Denosumab |
| Brand |
Xgeva® |
| Indication |
For the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland |
| Full pharmacoeconomic assessment commissioned by HSE |
15/08/2011 |
| NCPE assessment completed |
08/12/2011 |
| NCPE assessment outcome |
Denosumab (Xgeva®) is considered a cost-effective therapy for the prevention of skeletal-related events in adults with bone metastases from solid tumours in the Irish healthcare setting. |
